TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Study to Evaluate a BCG Challenge Model as a Method of Assessing Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A, Alone and in Combination
Brief Summary: The purpose of this study is to evaluate the BCG 'challenge' model a four-arm study design has been chosen. Twelve subjects will be recruited into each arm of the study. Allocation of BCG-naïve volunteers to either group A or B, and BCG-vaccinated volunteers to either group C or D, will be performed on a one-to-one alternating basis. Subjects in each group will be challenged by BCG administered intradermally. Prior to challenge, pre-existing immunity to TB will be induced by vaccination with BCG, MVA85A, and both in combination (when compared to BCG- \& MVA85A-naïve individuals). BCG quantification will be assessed by analysing the tissue obtained in a punch biopsy of volunteers' skin over the site of BCG 'challenge' vaccination. Any reduction in BCG quantification between groups will then be correlated to existing (and future) laboratory assays of vaccine-induced immune responses in order to identify potential immunological correlates of protection.


Options:
A: Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): N/A
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: AERAS-402, Biological: MVA85A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: AERAS-402, Biological: MVA85A | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: AERAS-402 | Intervention Type: BIOLOGICAL; Name: AERAS-402; Assigned to Arm(s): Group A, Group B, Group C | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): Group A, Group B
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: MVA85A/AERAS-485; Type: EXPERIMENTAL; Interventions: Biological: MVA85A/AERAS-485 | Intervention Type: BIOLOGICAL; Name: MVA85A/AERAS-485; Assigned to Arm(s): MVA85A/AERAS-485 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu | Intervention Type: BIOLOGICAL; Name: BCG: 100 microlitres ~ 2-8 x 105 pfu; Assigned to Arm(s): Group A, Group C | Intervention Type: BIOLOGICAL; Name: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu; Assigned to Arm(s): Group B, Group D

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Introducing Rapid Diagnostic Tests Into the Private Health Sector in Uganda: a Randomised Trial Among Registered Drug Shops to Evaluate Impact on Antimalarial Drug Use
Brief Summary: Most malaria deaths occur within 48 hours of onset of symptoms, and in rural areas with poor access to health facilities, home management of malaria (HMM) can improve the timeliness of treatment and reduce malaria mortality by up to 50%. In order to maximize both coverage and impact, artemisinin combination therapies (ACTs) should be deployed in HMM programmes, as well as in formal health facilities. Up to 80% of malaria cases are treated outside the formal health sector and shops are frequently visited as the first (and in some cases only) source of treatment. Strategies to deploy ACTs in Africa thus also need to examine the role of shops in home management and to ensure that drugs sold are appropriate. The current practice of presumptive treatment of any febrile illness as malaria (both at health facilities and in the context of HMM) based solely on clinical symptoms without routine laboratory confirmation, results in significant over-use of antimalarial drugs. With ACT being a more costly regimen, it is important to be more restrictive in its administration and rapid diagnostic tests (RDTs) provide a simple means of confirming malaria diagnosis in remote locations lacking electricity and qualified health staff.

This study therefore proposes to evaluate the feasibility, acceptability, and cost-effectiveness of using RDTs to improve malaria diagnosis and treatment by ocal drug shops in an area with high malaria transmission.


Options:
A: Arm Label: Current Practice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Malaria Rapid Diagnostic test | Intervention Type: DEVICE; Name: Malaria Rapid Diagnostic test; Assigned to Arm(s): Intervention Arm
B: Arm Label: nothing at home level; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home management of malaria; Type: EXPERIMENTAL; Interventions: Other: home/community case management | Arm Label: Home management of malaria and pneumonia; Type: EXPERIMENTAL; Interventions: Other: home/community case management | Intervention Type: OTHER; Name: home/community case management; Assigned to Arm(s): Home management of malaria, Home management of malaria and pneumonia
C: Arm Label: rapid diagnostic test; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test, Drug: Lumartem | Arm Label: Presumptive malaria treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Rapid diagnostic test; Assigned to Arm(s): rapid diagnostic test | Intervention Type: DRUG; Name: Lumartem; Assigned to Arm(s): rapid diagnostic test
D: Arm Label: Rapid Diagnostic Test; Type: EXPERIMENTAL; Interventions: Procedure: Rapid Diagnostic Test | Arm Label: No RDT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Rapid Diagnostic Test; Assigned to Arm(s): Rapid Diagnostic Test

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Brief Summary: This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.


Options:
A: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
C: Arm Label: natalizumab; Type: EXPERIMENTAL; Interventions: Drug: natalizumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: natalizumab, Drug: Placebo | Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): Placebo, natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone (drug) | Intervention Type: DRUG; Name: Cyclophosphamide (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methylprednisolone (drug); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Brief Summary: This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.


Options:
A: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex
C: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
D: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Brief Summary: This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.


Options:
A: Arm Label: Fish oil concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fish oil concentrate | Arm Label: Placebo oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fish oil concentrate; Assigned to Arm(s): Fish oil concentrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo oil
B: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Brief Summary: This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.


Options:
A: Arm Label: Laquinimod; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BIOLOGICAL; Name: natalizumab; Assigned to Arm(s): N/A
C: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
D: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Smoking Cessation Advice Combined With a Detailed Discussion of the Spirometric Results With the Primary Care Practitioner on the Smoking Habit in Adult Smokers (ESPITAP)
Brief Summary: The purpose of this study is to evaluate the effectiveness of the spirometric results information advice about the smoking habit the investigators designed an intervention trial in primary care.

Hypothesis: In adult smokers, smoking cessation advice combined with a discussion of the spirometric tests on the part of the practitioner achieves a higher rate of tobacco reduction and abandonment than just smoking cessation advice.

Expected results: In adult smokers, a detailed discussion of the results yielded by spirometry tests together with brief smoking cessation advice on the part of the primary care practitioner can facilitate tobacco reduction and abandonment.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
B: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation advice, Behavioral: Spirometry and smoking cessation advice | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Spirometry and smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling
C: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling and spirometry | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: Behavioral: Smoking cessation advice | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling and spirometry; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Lifestyle counseling
D: Arm Label: Basic Internet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Internet | Arm Label: Enhanced Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet | Arm Label: Enhanced Internet plus Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet + phone | Intervention Type: BEHAVIORAL; Name: Basic Internet; Assigned to Arm(s): Basic Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet; Assigned to Arm(s): Enhanced Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet + phone; Assigned to Arm(s): Enhanced Internet plus Phone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Smoking Cessation Advice Combined With a Detailed Discussion of the Spirometric Results With the Primary Care Practitioner on the Smoking Habit in Adult Smokers (ESPITAP)
Brief Summary: The purpose of this study is to evaluate the effectiveness of the spirometric results information advice about the smoking habit the investigators designed an intervention trial in primary care.

Hypothesis: In adult smokers, smoking cessation advice combined with a discussion of the spirometric tests on the part of the practitioner achieves a higher rate of tobacco reduction and abandonment than just smoking cessation advice.

Expected results: In adult smokers, a detailed discussion of the results yielded by spirometry tests together with brief smoking cessation advice on the part of the primary care practitioner can facilitate tobacco reduction and abandonment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: motivational counseling | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Intervention Type: BEHAVIORAL; Name: motivational counseling; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Respiragene test and risk score; Type: EXPERIMENTAL; Interventions: Genetic: Respiragene test and risk score | Intervention Type: GENETIC; Name: Respiragene test and risk score; Assigned to Arm(s): Respiragene test and risk score
C: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education
D: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation advice, Behavioral: Spirometry and smoking cessation advice | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Spirometry and smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Smoking Cessation Advice Combined With a Detailed Discussion of the Spirometric Results With the Primary Care Practitioner on the Smoking Habit in Adult Smokers (ESPITAP)
Brief Summary: The purpose of this study is to evaluate the effectiveness of the spirometric results information advice about the smoking habit the investigators designed an intervention trial in primary care.

Hypothesis: In adult smokers, smoking cessation advice combined with a discussion of the spirometric tests on the part of the practitioner achieves a higher rate of tobacco reduction and abandonment than just smoking cessation advice.

Expected results: In adult smokers, a detailed discussion of the results yielded by spirometry tests together with brief smoking cessation advice on the part of the primary care practitioner can facilitate tobacco reduction and abandonment.


Options:
A: Arm Label: Group I (standard care); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention | Arm Label: Group II (enhanced care); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention, Other: Tobacco Cessation Counseling | Arm Label: Group III (intensive care); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention, Behavioral: Telephone-Based Intervention, Other: Tobacco Cessation Counseling | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Group I (standard care), Group II (enhanced care), Group III (intensive care) | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Intervention; Assigned to Arm(s): Group I (standard care), Group II (enhanced care), Group III (intensive care) | Intervention Type: BEHAVIORAL; Name: Telephone-Based Intervention; Assigned to Arm(s): Group III (intensive care) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group II (enhanced care), Group III (intensive care)
B: Arm Label: Enhanced PTSD Health Buddy and Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivation Interviewing Counseling | Arm Label: Usual PTSD Health Buddy Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivation Interviewing Counseling; Assigned to Arm(s): Enhanced PTSD Health Buddy and Motivational Interviewing
C: Intervention Type: BEHAVIORAL; Name: Coping-focused counseling telephone calls; Assigned to Arm(s): N/A
D: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation advice, Behavioral: Spirometry and smoking cessation advice | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Spirometry and smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling

Answer: D